SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)

$PBYI
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $PBYI alert in real time by email
SC 13G/A 1 tv01759-pumabiotechnologyinc.htm SCHEDULE 13G/A pumabiotechnologyinc

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934
(Amendment No.: 10)*

Name of issuer:  Puma Biotechnology Inc

Title of Class of Securities:  Common Stock

CUSIP Number:  74587V107

Date of Event Which Requires Filing of this Statement: December 29, 2023

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on the following page(s))

 

 

13G

CUSIP No.:  74587V107

1.  NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

The Vanguard Group - 23-1945930

2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

A. 

B.  X

3.  SEC USE ONLY

4.  CITIZENSHIP OF PLACE OF ORGANIZATION

Pennsylvania

(For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

5.  SOLE VOTING POWER

0

6.  SHARED VOTING POWER

0

7.  SOLE DISPOSITIVE POWER

3,787,638

8.  SHARED DISPOSITIVE POWER

14,443

9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,802,081

10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

N/A

11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

7.99%

12.  TYPE OF REPORTING PERSON

IA

 

 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G
Under the Securities Act of 1934

Item 1(a) - Name of Issuer:

Puma Biotechnology Inc

Item 1(b) - Address of Issuer's Principal Executive Offices:

10880 Wilshire Boulevard, Suite 2150
Los Angeles, CA 90024-4101

Item 2(a) - Name of Person Filing:

The Vanguard Group - 23-1945930

Item 2(b) – Address of Principal Business Office or, if none, residence:

100 Vanguard Blvd.
Malvern, PA 19355

Item 2(c) – Citizenship:

Pennsylvania

Item 2(d) - Title of Class of Securities:

Common Stock

Item 2(e) - CUSIP Number

74587V107

Item 3 - Type of Filing:

This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

Item 4 - Ownership:

  (a) Amount Beneficially Owned:

  (b) Percent of Class:

 

 

(c)  Number of shares as to which such person has:

(i)  sole power to vote or direct to vote:  

(ii)  shared power to vote or direct to vote:  

(iii)  sole power to dispose of or to direct the disposition of:  

(iv)  shared power to dispose or to direct the disposition of:  

Comments:

The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

Item 5 - Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

No one other person's interest in the securities reported herein is more than 5%.

Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

Not applicable

Item 8 - Identification and Classification of Members of Group:

Not applicable

Item 9 - Notice of Dissolution of Group:

Not applicable

Item 10 - Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:  February 13, 2024

By /s/ Ashley Grim
Name: Ashley Grim
Title:  Head of Global Fund Administration

Get the next $PBYI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PBYI

DatePrice TargetRatingAnalyst
9/28/2021$11.00Neutral → Buy
Citigroup
9/28/2021Neutral → Buy
Citigroup
8/6/2021$13.00 → $6.00Sector Perform
RBC Capital
8/6/2021$9.00 → $8.00Sell
Goldman Sachs
More analyst ratings

$PBYI
Press Releases

Fastest customizable press release news feed in the world

See more
  • Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that clinical data on neratinib will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR Annual Meeting will be held at the McCormick Place in Chicago, Illinois, from April 25–30, 2025. The title of the poster that will be presented is now available on the AACR Annual Meeting website at https://www.abstractsonline.com/pp8/#!/20273/presentation/10447. The full poster will be available on the Puma website concurrent with the live presentation. Poster Session: First-in-Human Phase I Clinical Trials 1 Abstract CT071: Title: Phase I trial of trastuzumab deruxtecan in co

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on March 4, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, March 1, 2025, a

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on Tuesday, March 11, at Barclays 27th Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach. A live webcast of the presentation will be available on the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for replay for 30 days. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovat

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PBYI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PBYI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PBYI
SEC Filings

See more

$PBYI
Leadership Updates

Live Leadership Updates

See more
  • Puma Biotechnology to Join Russell 3000 Index

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000® Index at the conclusion of Russell Investments' annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S. markets open on July 1, according to a preliminary list of additions posted on May 24. "We are very pleased to be included in the widely referenced Russell Indexes," said Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology. "We believe that inclusion in the Russell 3000 will benefit our stockholders by increasing liquidity and providing exposure to a broader base of institutional investor

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

    Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. "Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "As we intend to expand our pipeline product portfolio into oncology, we are excited to add the wisdom and expertise that Alessandra can bring to our impressive leadership team. Her experience in developing both large and

    $EPIX
    $PBYI
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Toragen, Inc. Announces the Appointment of Board of Directors and Senior Staff

    Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), announced today the appointment of Mr. Paul Engler, of Amarillo, Texas, to the Board of Directors of the Company. Additionally, Toragen announced the appointment of Cheryl Collett as CFO, effective June 20, 2022, and Dr. Richard Lumpkin as Director, Research & Development, effective July 1, 2022. Mr. Engler is the founder of Cactus Feeders. In 1960, he started the first cattle-feeding oper

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PBYI
Financials

Live finance-specific insights

See more
  • Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the fourth quarter and full year 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net for the fourth quarter of 2024 was $54.4 million, compared to $53.2 million in the fourth quarter of 2023. Product revenue, net for the full year 2024 was $195.2 million, compared to $203.1 million in 2023. Based on accounting principles generally accepted in the United Stat

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 27, 2025, following the release of its fourth quarter and full year 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approx

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology Reports Third Quarter 2024 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2024. Unless otherwise stated, all comparisons are for the third quarter of 2024 compared to the third quarter of 2023. Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma's first commercial product. Product revenue, net in the third quarter of 2024 was $56.1 million, compared to $51.6 million in the third quarter of 2023. Product revenue, net in the first nine months of 2024 was $140.8 million, compared to $149.9 million in the first nine months of 2023. Based on accounting principles generally accepted in the United States (GA

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PBYI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more